Pharma Bio Serv Inc (PBSV) 0.8600 $PBSV Pharma-Bio Serv

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Pharma Bio Serv Inc (PBSV) 0.8600 $PBSV

Pharma-Bio Serv to Present at 6th Annual LD Micro Invitational Conference on June 8th, 2016
ACCESSWIRE - Tue May 31, 7:30AM CDT
DORADO, PUERTO RICO / ACCESSWIRE / May 31, 2016 / Pharma-Bio Serv, Inc. (Pharma-Bio Serv or the Company) (OTCQB: PBSV), a compliance, project management and technology transfer support consulting firm, that provides services to the pharmaceutical, biotechnology, chemical, medical device, cosmetic, food and allied products industries, today announced that Victor Sanchez, CEO, would be a featured presenter at the 6th annual LD Micro Invitational on June 8th, 2016 at 11:30am PST, Track 2 at the Luxe Sunset Hotel in Los Angeles, CA. Management will also be available for one-on-one meetings on June 8 and 9, 2016.

Pharma-Bio Serv Announces Results for the Quarter Ended January 31, 2016
ACCESSWIRE - Wed Mar 16, 3:40PM CDT
DORADO, PUERTO RICO / ACCESSWIRE / March 16, 2016 / Pharma-Bio Serv, Inc. (Pharma-Bio Serv or the Company) (OTCQB: PBSV), a compliance, project management and technology transfer support consulting firm, that provides services to the pharmaceutical, biotechnology, chemical, medical device, cosmetic, food and allied products industries, today announced net revenues of $4.9 million for the quarter ended January 31, 2016, a decrease of approximately $1 million, or 17%, when compared to the same period last year. The revenue decrease is mainly attributable to a decline in projects in the Puerto Rico, United States and Europe consulting markets of $0.7, $0.5 and $0.2 million, respectively, partially offset by a gain in the Puerto Rico Lab operation of approximately $0.3 million. Other Company divisions sustained minor revenue gains/losses or remained constant, when compared to the same period last year.

Pharma-Bio Serv Announces Total Net Revenues of $23.4 Million and Net Income of $1.6 Million for the Year Ended October 31, 2015
ACCESSWIRE - Fri Jan 29, 4:13PM CST
DORADO, PUERTO RICO / ACCESSWIRE / January 29, 2016 / Pharma-Bio Serv, Inc. (Pharma-Bio Serv or the Company) (OTCQB: PBSV), a compliance, project management and technology transfer support consulting firm, that provides services to the pharmaceutical, biotechnology, chemical, medical device, cosmetic, food and allied products industries, today announced total net revenues of $23.4 million for the year ended October 31, 2015, a decrease of approximately $4.2 million, or 15.1%, when compared to last year. The revenue decrease is mainly attributable to a decline from projects in the United States and Europe consulting markets.

Pharma-Bio Serv to Present at the LD Micro Conference on December 2, 2015
ACCESSWIRE - Tue Nov 24, 3:30PM CST
DORADO, PUERTO RICO / ACCESSWIRE / November 24, 2015 / Pharma-Bio Serv, Inc. (OTCQB: PBSV), a compliance, project management and technology transfer support consulting firm, that provides services to the pharmaceutical, biotechnology, chemical, medical device, cosmetic, food and allied products industries, today announced that the Company will be a featured presenter at the 8th annual LD Micro Main Event Conference. Victor Sanchez, CEO will present Pharma-Bio Serv's business model and growth strategy at 4:30pm PST on December 2, 2015 in Track 5 at the Luxe Sunset Hotel in Los Angeles, CA.

Pharma-Bio Serv Announces Results for the Three and Nine Months Ended July 31, 2015
ACCESSWIRE - Mon Sep 14, 3:31PM CDT
DORADO, PUERTO RICO / ACCESSWIRE / September 14, 2015 / Pharma-Bio Serv, Inc. (Pharma-Bio Serv or the Company) (OTCQB: PBSV), a compliance, project management and technology transfer support consulting firm, that provides services to the pharmaceutical, biotechnology, chemical, medical device, cosmetic, food and allied products industries, today announced net revenues for the three and nine months ended July 31, 2015 of $6.2 and $17.5 million, respectively, a decrease of approximately $0.6 and $2.9 million, or 9.6% and 14.3%, respectively, when compared to the same periods last year. The revenue decrease is mainly attributable to declines in the United States and Europe consulting markets of $1.1 and $0.3 million and $4.1 and $0.8 million, for the three months and nine months ended July 31, 2015, as compared to the same periods last year, respectively, partially offset by gains in the Puerto Rico consulting business of approximately $0.8 and $2.0 million, respectively. Latin America projects, managed from Puerto Rico, contributed to Puerto Rico consulting gains in the amount of $0.2 and $1.2 million for the three and nine months ended July 31, 2015, when compared to the same periods last year, respectively.

Pharma-Bio Serv Announces Results for the Three and Six Months Ended April 30, 2015
ACCESSWIRE - Mon Jun 15, 4:15PM CDT
DORADO, PUERTO RICO / ACCESSWIRE / June 15, 2015 / Pharma-Bio Serv, Inc. (Pharma-Bio Serv or the Company) (OTCQB: PBSV), a compliance, project management and technology transfer support consulting firm, that provides services to the pharmaceutical, biotechnology, chemical, medical device, cosmetic, food and allied products industries, today announced net revenues for the three and six months ended April 30, 2015 of $5.4 and $11.3 million, respectively, a decrease of approximately $1.1 and $2.3 million, or 17.2% and 16.6%, respectively, when compared to the same periods last year. The revenue decrease is mainly attributable to declines in the United States and Europe consulting markets of $1.4 and $0.2 million, and $2.9 and $0.5, for the three months and six months ended April 30, 2015, as compared to the same periods last year respectively, partially offset by gains in the Puerto Rico consulting business of $0.6 and $1.3 million, respectively. Latin America projects, managed from Puerto Rico, contributed to Puerto Rico consulting gains in the amount of $0.5 and $1.0 million for the three and six months periods ended April 30, 2015 when compared to the same periods last year, respectively.

Pharma-Bio Serv Announces Total Net Revenues of $27.6 Million and Net Income of $2.4 Million for the Year Ended October 31, 2014
ACCESSWIRE - Thu Jan 29, 5:17PM CST
DORADO, PUERTO RICO / ACCESSWIRE / January 29, 2015 / Pharma-Bio Serv, Inc. (Pharma-Bio Serv or the Company) (OTCQB: PBSV), a compliance, project management and technology transfer support consulting firm, that provides services to the pharmaceutical, biotechnology, chemical, medical device, cosmetic, food and allied products industries, today announced total net revenues of $27.6 million for the year ended October 31, 2014, a decrease of approximately $5.5 million, or 16.7%, when compared to the same period last year. The revenue decrease is mainly attributable to a decline from consulting projects in the United States and Europe.

Pharma-Bio Serv Appoints Víctor Sánchez as President and Chief Executive Officer Effective January 1, 2015
ACCESSWIRE - Tue Dec 02, 8:01AM CST
DORADO, PUERTO RICO / ACCESSWIRE / December 2, 2014 / Pharma-Bio Serv, Inc. (Pharma-Bio Serv or the Company) (OTCQB: PBSV), a compliance, project management and technology transfer support consulting firm, that provides services to the pharmaceutical, biotechnology, chemical, medical device, cosmetic, food and allied products industries, announced today that the Board of Directors has appointed Víctor Sánchez as President and Chief Executive Officer, effective January 1, 2015.
MRK: 57.25 (+0.61)

Pharma-Bio Serv Retains T.R. Winston & Company to Enhance Growth Opportunities Through Business Development, Mergers & Acquisitions, and to Review Strategic Alternatives
ACCESSWIRE - Mon Dec 01, 8:01AM CST
DORADO, PUERTO RICO / ACCESSWIRE / December 1, 2014 / Pharma-Bio Serv, Inc. (Pharma-Bio Serv or the Company) (OTCQB: PBSV), a compliance, project management and technology transfer support consulting firm, that provides services to the pharmaceutical, biotechnology, chemical, medical device, cosmetic, food and allied products industries, announced today that it has retained T.R. Winston & Company (T.R. Winston) in order to assist Pharma-Bio Serv in enhancing the Company's growth strategy through business development, and mergers and acquisitions.

Pharma-Bio Serv Signs Strategic Collaboration Agreement With Quality Technical Iberica, S.L.
Marketwired - Thu Oct 09, 3:05PM CDT
Pharma-Bio Serv. (OTCQB: PBSV), a compliance, project management and technology transfer support consulting firm, announced today that it has signed a three-year strategic collaboration agreement with Quality Technical Iberica, S.L ("QTI", a Spain-based company specializing in Calibrations, Validation, HVAC and Clean Room Qualification services.

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Celltrion Unveils New Data on Infliximab: ACG 2026 Insight

Updated Category News Views 36

First Impressions: Celltrion's Latest Revelation Alright, let's jump straight into it. Celltrion USA is flaunting its latest findings on ZYMFENTRA® (infliximab-dyyb) for Crohn's disease and ulcerative colitis right at the American College of Gastroenterology's (ACG) grand event in 2026. If you've been watching the healthcare sector, this is significant news. It's got all...

Continue Reading
Sebela Pharma's Tegoprazan Posts Strong Phase 3 Data

Updated Category News Views 26

Spotlight on Tegoprazan: A New Player on the GERD Field Sometimes, a pharma company turns heads with data that speaks for itself. This time, Sebela Pharmaceuticals is doing just that with Tegoprazan's phase 3 results, shining a light on an area overlooked for too long: non-erosive reflux disease (NERD). Showing promise in its latest trials, Tegoprazan is muscling into the...

Continue Reading
LEGO Mashes Star Wars and Marvel for Fans' Delight

Updated Category News Views 36

A New Chapter in LEGO's Story Well, well, what do we have here? LEGO's throwing down the gauntlet. For the first time, they're asking fans to merge two colossal universes: Star Wars and Marvel. Talk about a brains-and-bricks bonanza! Announced at New York Comic Con with some star power from Kevin Smith, this LEGO Ideas challenge opens doors for fan creativity that might...

Continue Reading
Duolingo Faces Lawsuit Over Alleged Investor Missteps

Updated Category News Views 41

Fasten your seatbelts, folks. We're diving into a legal tussle that could shake things up for Duolingo, Inc. (NASDAQ: DUOL). Investors who plunged into Duolingo shares between May 2, 2025, and February 26, 2026, might be feeling the heat now. They ought to brace for a class-action lawsuit frenzy with fingers pointed at Duolingo for allegedly pulling wool over investors'...

Continue Reading
AbbVie's SKYRIZI and RINVOQ Highlight IBD Control Advances

Updated Category News Views 36

A Deeper Look Into AbbVie's Latest Data Let's cut straight to the science, folks. At the recent American College of Gastroenterology 2026 Annual Scientific Meeting, AbbVie pulled the curtain on 22 fresh scientific abstracts that are really shaking things up in the field of inflammatory bowel disease (IBD) treatment. Data from the Phase 3 AFFIRM study shined especially...

Continue Reading
2026 Community Impact Week: Slam Dunk for Community Unity

Updated Category News Views 32

Alright, if you're looking for a story that gives you those warm fuzzy feelings while wrapping you in a big sports hug, here it is. Imagine this: you've got basketball legends, world-class athletes, and a corporate heavyweight, all huddling up to make a community impact that's more than just warm air. Hoops, Hope, and High Fives The NBA Cares x Sands Cares Community...

Continue Reading
Pacira BioSciences Faces Shareholder Revolt in M&A Deal

Updated Category News Views 4

A New Storm Brews Over Pacira's Sale to Viatris They say where there's smoke, there's fire, and it looks like Pacira BioSciences, Inc. (NASDAQ: PCRX) is running right into a bonfire thanks to their upcoming sale to Viatris Inc. On the face of it, shareholders are looking at a tidy $36.50 in cash per share, but not everyone's buying the deal as fair. Enter lawman Juan...

Continue Reading

Top 5 Most Recently Viewed Articles

AgEagle Aerial Systems Welcomes Kevin Lowdermilk to the Board

Updated Category News Views 103

AgEagle Aerial Systems Welcomes Kevin Lowdermilk to the Board AgEagle Aerial Systems Inc. (NYSE: UAVS), renowned for its top-tier unmanned aerial systems (UAS), is excited to announce the recent addition of Kevin Lowdermilk to its board of directors. His appointment, effective as of late October, marks a strategic enhancement to the company's leadership team, ensuring...

Continue Reading
Natera's Growth Continues Amid Legal Challenges and Market Wins

Updated Category News Views 413

Natera Faces Legal Challenges with Strong Market Performance Natera, Inc. (NASDAQ: NTRA) is a leader in the genetic testing industry, known for its groundbreaking contributions to oncology and women’s health. Recently, the company encountered an unfavorable jury decision in a legal battle concerning false advertising claims made against Guardant Health (NASDAQ: GH). The...

Continue Reading
Spreedly Sees Unprecedented Growth in Open Payments Sector

Updated Category News Views 110

Spreedly Surges Ahead in Open Payments Innovation Spreedly, a prominent leader in open payments, has recently showcased remarkable progress in revenue and customer expansion, marking a new chapter in the payment processing industry. With a growing clientele that spans across varied sectors, the company is redefining how digital transactions are handled worldwide. Key...

Continue Reading
Shelley Joyce Takes the Helm as CTO at TSG, Ramping Up Innovation

Updated Category News Views 431

TSG Appoints Shelley Joyce as New Chief Technology Officer In a significant move to enhance its technology initiatives, TSG (The Strawhecker Group) has announced the appointment of Shelley Joyce as the Chief Technology Officer (CTO). With her extensive background in the payments industry, Shelley is set to lead TSG’s technological advancements and cater to the evolving...

Continue Reading
Equillium Plans Engaging Event for Ulcerative Colitis Insights

Updated Category News Views 121

Equillium's Upcoming Event on Ulcerative Colitis Equillium, Inc. (NASDAQ: EQ), a biotechnology company focused on developing innovative therapeutics for autoimmune and inflammatory diseases, has announced an exciting virtual event featuring prominent thought leaders in the field of ulcerative colitis (UC). This event is scheduled for a Wednesday in November at 12 PM ET....

Continue Reading